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A 38-year-old HIV-positive female, recently started on antiretroviral therapy, presented in extremis. She had features
suggestive of an HIV-associated cardiomyopathy complicated by the following problems: a four-day-old stroke, extensive deep
venous thrombosis, and massive pulmonary embolism. She received intravenous streptokinase with rapid improvement, both
haemodynamically and, unexpectedly, neurologically. Our case illustrates that a positive outcome is potentially possible where the
two conditions coincide.
1.CaseReport
A 38-year-old female presented with a 2-day history of dys-
pnoea and pleuritic chest pain. She had developed a right
sided hemiplegia 4 days before the current presentation. She
was HIV positive with a CD4 count of 180, and she was
receiving highly active antiretroviral therapy.
On examination she was distressed, with a respiratory
rate of 30 breaths per minute, a low-volume pulse of 130
beats per minute, and a blood pressure of 70/30mmHg.
The jugular venous pressure was markedly elevated. On
palpation, the apex beat was myopathic and displaced,
there was a left parasternal heave and palpable pulmonary
component of the second heart sound. Auscultation revealed
a loud pulmonary component of the second heart sound
(P2)andathirdheartsoundattheleftsternaledge.Herright
leg was markedly swollen. She had a dense right hemiplegia
with absent power on the right.
Chest X-ray showed an increased cardiothoracic ratio.
ECG showed a sinus tachycardia and left bundle branch
block without features of acute right ventricular strain.
Doppler ultrasound conﬁrmed an extensive right-sided deep
vein thrombosis.
AhelicalCTpulmonaryangiogram demonstratedmulti-
pledefectsinmajorbranchesofbothpulmonaryarteriesand
multiple areas of pulmonary infarction (Figure 1). A CT
brain scan demonstrated recent left frontoparietal cere-
bral infarction (Figure 2). Echocardiography showed four-
chamber dilatation, a left ventricular ejection fraction of
13%, mitral regurgitation, and tricuspid regurgitation. Pul-
monary artery systolic pressure was 67mmHg. There was
no evidence of intramural thrombosis and no direct com-
munication between the right and left side of the heart was
demonstrated.
Fullbloodcountandroutinechemistrywereunremarka-
ble. A D-dimer test was positive and troponin T concentra-
tion was normal. Our ﬁnal diagnosis was that of HIV infec-
tion, probable HIV-associated cardiomyopathy, deep venous
thrombosis, and acute massive pulmonary thromboem-
bolism.
Thepatientwasunstable,tachycardic,andseverelyhypo-
tensive. Though mindful of her stroke, we administered stre-
ptokinase according to the standard protocol. Her haemo-
dynamic status improved markedly, and blood pressure
normalised. Signs of pulmonary hypertension improved. A
repeat CT pulmonary angiogram showed partial resolution
of the pulmonary emboli. To our surprise, her neurological
signs improved remarkably as well, with an improvement in
muscle power over several hours to near normal. A repeat
CT brain scan now demonstrated a rim of enhancement
around the infarction, reported as a haemorrhage, though
subsequently suggested to represent an area of luxury
perfusion.
She maintained her initial clinical improvement and
improved further over subsequent days on standard therapy
for heart failure. Intercostal drainage was required for a large2 Case Reports in Medicine
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Figure 1: (a) Axial computerised tomography pulmonary
angiogram showing ﬁlling defect in pulmonary artery. Similar
ﬁlling defects were found at multiple levels of the pulmonary artery
vasculature. (b) Coronal computerised tomography pulmonary
angiogram showing multiple ﬁlling defects in the pulmonary artery
and a triangular hypodensity in the right lower lung, which is most
likely a pulmonary infarct.
right haemorrhagic pleural eﬀusion secondary to pulmonary
infarction. She was discharged after 18 days on warfarin.
2. Discussion
Risk factors for thrombosis in our patient included immo-
bility, dilated cardiomyopathy, and her HIV status. HIV is
an independent risk factor for thrombosis. Antiretroviral
therapy does not appear to signiﬁcantly increase risk of
venous thromboembolism in HIV-positive patients [1].
The prothrombotic state in HIV-positive patients correlates
with the severity of HIV-associated immunosuppression.
The mechanism of this increased prothrombotic state in
HIV patients is unknown. However, various abnormalities
predisposing to a prothrombotic state have been reported,
including the presence of antiphospholipid antibodies and
lupus anticoagulant, deﬁciencies of protein C, protein S,
heparin cofactor II, and antithrombin, and increased levels
of von Willebrand factor and D-dimers [2, 3].
Our patient demonstrated global myocardial impair-
ment, probably on the basis of an HIV-associated car-
diomyopathy. Her sudden deterioration and acute onset of
pulmonary hypertension suggested the onset of “clinically
massive” or high-risk pulmonary embolism [4], which is
associated with a high short-term mortality [4], especially
during the ﬁrst few hours [5]. There is consensus that
such patients should be oﬀered urgent recanalization of
the pulmonary arteries, whether by thrombolysis or by
mechanical means, in order to reverse right ventricular
pressure overload and failure [5, 6].
An ischaemic stroke within the past 6 months is accepted
as an absolute contraindication to thrombolysis [4], though
consensus guidelines note that even absolute contraindica-
tions may be considered relative in patient with immediately
life-threatening high-risk pulmonary embolism.
We believed our patient to be unsuitable for embolec-
tomy. With her informed consent, we proceeded to throm-
bolysis despite the stroke. In response to thrombolysis, the
patient improved dramatically and repeat CT angiography
revealed partial resolution of the thrombi. To our surprise,
there was a prompt, marked improvement in the patient’s
neurological status.
Thrombolysis is now recommended as initial treatment
for ischaemic stroke presenting within 3 hours [7]o r4 . 5
hours [8]. Therapy carries a risk of symptomatic intracranial
haemorrhage less than 7% [7]. Currently no authority
recommendsthrombolysisfourdaysaftertheonsetofstroke.
There are three case reports of patients with coexis-
tent pulmonary embolism and stroke given thrombolysis.
Pelletier et al. [9], Pavesi et al. [10], and Allport and
Butcher [11] reported patients with pulmonary embolus and
paradoxical embolism resulting in acute stroke, of recent
onset, who improved (neurologically and haemodynami-
cally) following thrombolysis. All patients received throm-
bolysis within hours of ﬁrst presentation. Unfortunately,
we did not perform provocation tests in our patient, and
thus we were not able to rule out a transient right-to-left
shunt. Perhaps, similar to the above-mentioned cases, our
patient also had a paradoxical embolism. Our patient diﬀers
from aforementioned case reports in that she only received
thrombolysis 4 days following the onset of neurological
symptoms. Thrombolysis appeared to result in signiﬁcant
improvement in both the pulmonary embolism and the
stroke. Though the neurological improvement may be
coincidental, we believe that thrombolysis may have allowed
reperfusion of a penumbra of critical cerebral ischaemia,Case Reports in Medicine 3
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Figure 2: (a) Axial computerised tomography (unenhanced) brain showing a wedge-shaped hypodensity in the left frontopareital area with
extension across both gray and white matter, which is in keeping with a cerebral infarct. (b) Axial computerised tomography (enhanced)
brain showing hyperdensity in the left-hand side in the area of previous ischaemia. (c) Coronal computerised tomography (enhanced) brain
showing hyperdensity in the left-hand side in the area of previous ischaemia.
possibly augmented by an increase in cerebral perfusion
pressure as her haemodynamic status improved.
During the evolution of an ischaemic stroke, there is
a gradient of hypoperfusion [12]. Areas with the least
perfusion progress to irreversible damage and are termed
the “necrotic core.” The remaining hypoperfused tissue is
divided into two compartments, that is, the “penumbra
and oligaemia.” Tissue within the penumbra is potentially
salvageable [13]. Most patients exhibit substantial volumes
of penumbra for many hours [14]o re x c e p t i o n a l l y ,d a y s
afterstrokeonset[15].Theoligaemiccompartment,suﬀersa
milderdegreeofhypoperfusionandisnot normallyatriskof
infarction [13]. However, secondary events such as systemic
hypotension, intracranial hypertension, or hyperglycaemia
may result in the oligaemic area transforming into a
penumbral state and even worse, the necrotic core.
European Cooperative Acute Stroke Study (ECASS) III,
a randomized, placebo-controlled, phase-three trial, tested
the eﬃcacy and safety of rt-PA administered 3 to 4.5 hours
after symptom onset [16]. ECASS III conﬁrmed the National
Institute of Neurological Disorders and Stroke (NINDS)
[17] study ﬁnding of a signiﬁcant beneﬁt with rt-PA in4 Case Reports in Medicine
the primary end point at 3 months. Additionally, rt-PA
administered 3–4.5 hours after the onset of stroke symptoms
resulted in a signiﬁcant improvement of clinical outcome
without increasing the risk of intracebral haemorrhage. The
results of the ECASS III trial and pooled analysis data
prompted the American Heart Association/American Stroke
Associationtoadvisethatrt-PAshouldbeoﬀeredbetween3–
4.5 hours to select patients [18]. The thrombolytic treatment
window period for acute stroke is in evolution [19]. It is
postulated that physiologic imaging will more eﬀectively
guide the selection of patients for thrombolysis and may, for
select patients, enable the window period for thrombolysis
to increase even beyond 4.5 hours [13]. We postulate that
our patient had “characteristics” that allowed for successful
thrombolysis so late after initial neurological symptoms. The
aforementioned“characteristics”arecurrentlyunknown,but
advancingknowledgeinmedicalsciencewillperhapsprovide
answers in the not too distant future.
In summary, thrombolysis proved safe and eﬀective, and
it was accompanied by unexpected neurological improve-
ment.
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